Ceftolozane/tazobactam for Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis adult patients: a case series

Rational Design and Antimicrobial Potency Assessment of Abaecin Analogues

“…Moreover, it serves as a main contributor to morbidity and mortality in patients suffering from cystic fibrosis and chronic obstructive pulmonary disease. 3,5 Furthermore, the efflux pumps, 6 unique outer membrane (OM) structure, 7 and biofilm formation 8 in P. aeruginosa are likely to serve as significant sources of antibiotic resistance, either through intrinsic resistance or acquired mutational resistance. As reported in numerous epidemiological studies, P. aeruginosa clinical isolates have exhibited an escalating resistance to a broad spectrum of antibiotics, including fourth-generation cephalosporins.…”

“…aeruginosa, as a Gram-negative (G – ), nonfermenting, and rod-shaped bacterium, is one of the prominent pathogens responsible for both hospital-acquired and community-acquired infections that impact diverse anatomical sites such as the integumentary system, soft tissues, lower respiratory tract, peritoneal cavity, and even bloodstream (septicemia). Moreover, it serves as a main contributor to morbidity and mortality in patients suffering from cystic fibrosis and chronic obstructive pulmonary disease. , Furthermore, the efflux pumps, unique outer membrane (OM) structure, and biofilm formation in P. aeruginosa are likely to serve as significant sources of antibiotic resistance, either through intrinsic resistance or acquired mutational resistance.…”